Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jul 12 04:00PM ET
9.64
Dollar change
+0.34
Percentage change
3.66
%
IndexRUT P/E- EPS (ttm)-4.31 Insider Own64.51% Shs Outstand33.18M Perf Week53.50%
Market Cap568.95M Forward P/E- EPS next Y-3.17 Insider Trans0.94% Shs Float20.95M Perf Month20.05%
Income-236.92M PEG- EPS next Q-0.04 Inst Own38.50% Short Float24.90% Perf Quarter15.31%
Sales2.10M P/S270.93 EPS this Y42.29% Inst Trans-0.70% Short Ratio15.44 Perf Half Y-12.88%
Book/sh2.74 P/B3.52 EPS next Y-16.46% ROA-56.49% Short Interest5.22M Perf Year-7.22%
Cash/sh4.98 P/C1.93 EPS next 5Y- ROE-118.26% 52W Range3.81 - 17.70 Perf YTD16.00%
Dividend Est.- P/FCF- EPS past 5Y-44.65% ROI-121.16% 52W High-45.54% Beta0.21
Dividend TTM- Quick Ratio7.98 Sales past 5Y19.85% Gross Margin-381.43% 52W Low153.02% ATR (14)0.86
Dividend Ex-Date- Current Ratio7.98 EPS Y/Y TTM16.68% Oper. Margin-12054.30% RSI (14)66.39 Volatility16.08% 10.57%
Employees224 Debt/Eq0.25 Sales Y/Y TTM32.31% Profit Margin-11255.25% Recom1.80 Target Price21.40
Option/ShortYes / Yes LT Debt/Eq0.21 EPS Q/Q37.87% Payout- Rel Volume2.09 Prev Close9.30
Sales Surprise-32.89% EPS Surprise-3.05% Sales Q/Q-4.79% EarningsMay 08 AMC Avg Volume337.90K Price9.64
SMA2035.51% SMA5015.75% SMA20012.92% Trades Volume705,270 Change3.66%
Date Action Analyst Rating Change Price Target Change
Feb-09-24Upgrade RBC Capital Mkts Sector Perform → Outperform $9 → $21
Dec-15-23Downgrade BofA Securities Buy → Neutral $8
Dec-07-23Downgrade H.C. Wainwright Buy → Neutral $11 → $7
Nov-09-22Resumed Jefferies Buy $61 → $55
Oct-17-22Initiated JP Morgan Neutral $27
Aug-29-22Initiated BofA Securities Buy $34
Dec-13-21Downgrade RBC Capital Mkts Outperform → Sector Perform $51
Nov-05-21Upgrade Wedbush Neutral → Outperform
Aug-26-21Initiated Morgan Stanley Overweight $100
Jan-29-21Initiated RBC Capital Mkts Outperform $121
Jul-12-24 09:35AM
May-29-24 07:00AM
May-10-24 02:38PM
May-09-24 07:38AM
May-08-24 10:55PM
05:55PM Loading…
05:55PM
04:10PM
May-07-24 07:00AM
May-03-24 10:00AM
Apr-30-24 12:00PM
Apr-17-24 08:30AM
Apr-10-24 07:00AM
Mar-07-24 10:52PM
05:45PM
04:10PM
09:55AM Loading…
Mar-01-24 09:55AM
Feb-14-24 09:55AM
Feb-01-24 07:00AM
Jan-16-24 08:38AM
Jan-03-24 07:00AM
Dec-08-23 04:09AM
Dec-06-23 02:44AM
Dec-05-23 04:01PM
Dec-01-23 05:32AM
Nov-27-23 03:52AM
Nov-22-23 02:46AM
Nov-21-23 02:48AM
Nov-16-23 09:55AM
Nov-14-23 07:28PM
Nov-13-23 04:10PM
03:49AM Loading…
03:49AM
Nov-07-23 07:00AM
Oct-25-23 02:46AM
Oct-23-23 02:48AM
Oct-20-23 09:29AM
Oct-05-23 07:29AM
Oct-03-23 04:05PM
Sep-20-23 04:36AM
Sep-06-23 07:00AM
Aug-10-23 08:59PM
Aug-03-23 05:25PM
04:10PM
Jul-05-23 06:46AM
Jul-03-23 04:01PM
Jun-30-23 09:48AM
Jun-22-23 08:14PM
07:58AM
Jun-21-23 05:17PM
Jun-02-23 05:30PM
Jun-01-23 07:00AM
May-31-23 07:00AM
May-30-23 07:00AM
May-25-23 11:58AM
May-12-23 10:15AM
09:05AM
May-02-23 07:00AM
Apr-28-23 11:50AM
Apr-19-23 07:00AM
Apr-13-23 04:05PM
Apr-06-23 12:23PM
Apr-01-23 09:17AM
Mar-30-23 06:05PM
04:05PM
Mar-27-23 07:00AM
Feb-02-23 07:00AM
Jan-17-23 07:00AM
Jan-09-23 07:00AM
Jan-03-23 07:00AM
Dec-11-22 10:00AM
Dec-01-22 07:00AM
Nov-16-22 06:37AM
Nov-08-22 07:00AM
Nov-03-22 10:25AM
09:05AM
Nov-02-22 04:05PM
Oct-27-22 02:06PM
Sep-06-22 07:00AM
Aug-08-22 06:45PM
04:10PM
Jul-04-22 02:04PM
Jun-01-22 07:00AM
May-20-22 12:07PM
May-10-22 07:00AM
May-09-22 04:16PM
May-06-22 07:00AM
Apr-09-22 09:35AM
Apr-06-22 04:39PM
Apr-05-22 04:56PM
Mar-30-22 03:06PM
02:14PM
01:29PM
11:57AM
12:56AM
Mar-29-22 11:41AM
09:00AM
08:54AM
07:59AM
07:41AM
06:01AM
02:00AM
IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The firm's product pipeline includes IGM-2323, which is a CD20 x CD3 bispecific IgM antibody designed to treat patients with B cell Non-Hodgkin's lymphoma and other B cell malignancies, IGM-8444, which is an IgM antibody targeting Death Receptor 5 for the treatment of patients with solid and hematologic malignancies, and IGM-7354, which will target the delivery of IL-15 with the goal of inducing immune cell stimulation and proliferation. The company was founded in 2010 and is headquartered in Mountain View, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schwarzer FredCEO AND PRESIDENTJun 14 '24Sale7.584,16431,544254,070Jun 18 07:42 PM
Harler Mary BethHead, Research & AutoimmunityJun 14 '24Sale7.581,57011,89385,227Jun 18 07:40 PM
Takimoto Chris HCHIEF MEDICAL OFFICERJun 14 '24Sale7.581,57011,89395,818Jun 18 07:44 PM
Tahir MisbahCHIEF FINANCIAL OFFICERJun 14 '24Sale7.581,57011,89388,848Jun 18 07:43 PM
Keyt BruceCHIEF SCIENTIFIC OFFICERJun 14 '24Sale7.581,1068,378197,769Jun 18 07:41 PM
Decker Lisa LynnCHIEF BUSINESS OFFICERJun 14 '24Sale7.589777,40160,029Jun 18 07:38 PM
Weber StevenPRINCIPAL ACCOUNTING OFFICERJun 14 '24Sale7.584953,75026,012Jun 18 07:45 PM
BAKER BROS. ADVISORS LPDirectorMar 28 '24Buy9.6297,473937,6323,753,480Mar 28 07:04 PM
BAKER BROS. ADVISORS LPDirectorMar 27 '24Buy9.2427,844257,1703,664,073Mar 28 07:04 PM
BAKER BROS. ADVISORS LPDirectorMar 26 '24Buy8.26270,0002,230,7673,638,533Mar 28 07:04 PM
Schwarzer FredCEO AND PRESIDENTMar 14 '24Sale10.174,18242,533216,651Mar 15 07:51 PM
Tahir MisbahCHIEF FINANCIAL OFFICERMar 14 '24Sale10.172,54325,86490,418Mar 15 07:53 PM
Takimoto Chris HCHIEF MEDICAL OFFICERMar 14 '24Sale10.172,53525,78294,388Mar 15 07:55 PM
Keyt BruceCHIEF SCIENTIFIC OFFICERMar 14 '24Sale10.171,84418,754171,856Mar 15 07:49 PM
Decker Lisa LynnCHIEF BUSINESS OFFICERMar 14 '24Sale10.171,57816,04961,006Mar 15 07:48 PM
Weber StevenPRINCIPAL ACCOUNTING OFFICERMar 14 '24Sale10.174644,71926,507Mar 15 07:57 PM
Schwarzer FredCEO AND PRESIDENTMar 13 '24Sale9.884,76547,055220,833Mar 15 07:51 PM
Tahir MisbahCHIEF FINANCIAL OFFICERMar 13 '24Sale9.882,89728,60892,961Mar 15 07:53 PM
Takimoto Chris HCHIEF MEDICAL OFFICERMar 13 '24Sale9.882,88928,52996,923Mar 15 07:55 PM
Keyt BruceCHIEF SCIENTIFIC OFFICERMar 13 '24Sale9.882,10120,748173,700Mar 15 07:49 PM
Decker Lisa LynnCHIEF BUSINESS OFFICERMar 13 '24Sale9.881,79817,75662,584Mar 15 07:48 PM
Weber StevenPRINCIPAL ACCOUNTING OFFICERMar 13 '24Sale9.885295,22426,971Mar 15 07:57 PM
Keyt BruceCHIEF SCIENTIFIC OFFICERMar 01 '24Option Exercise0.933,0262,8144,039Mar 05 07:34 PM
BAKER BROS. ADVISORS LPDirectorDec 15 '23Buy6.55288,0071,887,5313,390,323Dec 15 05:32 PM
BAKER BROS. ADVISORS LPDirectorDec 14 '23Buy6.50157,3701,023,1573,123,585Dec 15 05:32 PM
BAKER BROS. ADVISORS LPDirectorDec 13 '23Buy5.9687,316520,7762,977,836Dec 15 05:32 PM
Schwarzer FredCEO and PresidentDec 13 '23Sale5.7817,576101,558102,848Dec 15 07:20 PM
Keyt BruceChief Scientific OfficerDec 13 '23Sale5.787,57443,764129,551Dec 15 07:19 PM
Decker Lisa LynnChief Business OfficerDec 13 '23Sale5.784,36925,24535,632Dec 15 07:18 PM
Takimoto Chris HChief Medical OfficerNov 29 '23Sale6.211,1807,33153,562Dec 01 07:03 PM
Decker Lisa LynnChief Business OfficerNov 29 '23Sale6.211,1807,33140,001Dec 01 07:01 PM
Gauthier GeorgeChief Commercial OfficerNov 29 '23Sale6.211,1807,33139,642Dec 01 07:02 PM
Tahir MisbahChief Financial OfficerNov 27 '23Sale5.061,3376,76449,608Nov 29 08:49 PM
Schwarzer FredCEO and PresidentNov 27 '23Sale5.061,3376,764120,424Nov 29 08:48 PM
Keyt BruceChief Scientific OfficerNov 27 '23Sale5.069334,720137,125Nov 29 08:47 PM
Gauthier GeorgeChief Commercial OfficerOct 02 '23Sale7.959357,43039,082Oct 03 07:55 PM